Damora Therapeutics, Inc. (NASDAQ:DMRA)
| Market Cap | $1.44B+38.5% |
| Revenue (ttm) | $0 |
| Net Income | -$291.68M-1741.0% |
| EPS | -$4.71-915.0% |
| Shares Out | 61.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 643,377 |
| Open | $23.81 |
| Previous Close | $24.30 |
| Day's Range | $23.09 - $24.51 |
| 52-Week Range | $15.76 - $38.33 |
| Beta | 1.51 |
| Analysts | Buy |
| Price Target | $52.50(+126.10%) |
| Earnings Date | Mar 18, 2027 |
About DMRA
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc. Stock Analysis — InsiderScore
Damora Therapeutics, Inc. scored higher than 3% of companies evaluated by InsiderBuying, and ranked 90th out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Damora Therapeutics, Inc. bought $252.9K of stock across 1 purchase in the last 90 days, the largest of them $252.9K.
The average purchase added about 3% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating DMRA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 18, 2027Earnings report
$DMRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DMRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DMRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DMRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DMRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DMRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DMRA
| IWMiShares Russell 2000 ETF | $29.92M |
| XBIState Street SPDR S&P Biotech ETF | $18.03M |
| VXFVanguard Extended Market ETF | $12.07M |
| IWOiShares Russell 2000 Growth ETF | $7.47M |
| SCHASchwab U.S. Small-Cap ETF | $6.25M |
| VTWOVanguard Russell 2000 ETF | $5.97M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from DMRA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mix of corporate updates and routine announcements; trial launch question suggests uncertainty, offset by standard financial reporting.
Recent Insider Activity
Insider Score Trend Over Time
-20.5 since Sep 28Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.83% |
| WCEO | Hypatia Women CEO ETF | 0.19% |
| XBI | State Street SPDR S&P Biotech ETF | 0.16% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.15% |
| OPTZ | Optimize Strategy Index ETF | 0.14% |
| PJSM | PGIM Jennison Small-Mid Cap Core Equity ETF | 0.12% |
| FFSM | Fidelity Fundamental Small-Mid Cap ETF | 0.06% |
| FSMO | Fidelity Fundamental Small-Mid Cap ETF | 0.06% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.05% |
| IWO | iShares Russell 2000 Growth ETF | 0.05% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.05% |
| PWS | Pacer WealthShield ETF | 0.03% |
Weight is the stock’s share of each fund’s holdings.
